João Cândido Spezia de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
João Cândido Spezia de Souza has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Natan Lucca Lima
Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Santa Catarina, Brazil
3 shared publications - Bárbara Ghizoni Maggi
Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Brazil
2 shared publications - Davi Orli Machado Grüdtner
Universidade Federal de Santa Catarina, Brasil
2 shared publications - Gustavo Rassier Isolan
Centro Avançado de Neurologia e Neurocirurgia, Porto Alegre, RS, Brasil
2 shared publications - Marcos Henrique da Silva Mezzari
Faculty of Medicine, Federal University of Santa Catarina, Araranguá, Brazil
2 shared publications - Ana Carolina Lobor Cancelier
Department of Pediatrics, University of Southern Santa Catarina, Tubarão, Brazil
1 shared publication
Latest Publications
- 7 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Vagus nerve stimulation in pediatric patients with Lennox–Gastaut syndrome: a systematic review
- 7 September 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Vagus nerve stimulation in pediatric patients with Lennox–Gastaut syndrome: a systematic review
- 20 November 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (6) , 1-12
Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.
- 20 November 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (6) , 1-12
Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis
Glioblastoma is an aggressive brain tumor with median survival under 2 years despite standard therapy. At recurrence, treatment options are limited, and regorafenib has emerged as a promising option. A systematic search was conducted through Pubmed, Cochrane Library, Embase, and Web of Science for studies on regorafenib in adult recurrent glioblastoma, and a single-arm meta-analysis with random-effects model was performed to pool the data. Across ten studies (724 patients), median overall survival (OS) was 7.2 months and median progression-free survival (PFS) was 2.6 months, with a 12-month OS of 22.5% and a 6-month PFS of 14.9%. Disease control rate (DCR) was 36.1%, including stable disease (SD) of 26.6% and a partial response of 8.5%; progressive disease occurred in 60.9%, and grade 3-4 adverse events in 31.4%. Meta-regression suggested MGMT methylation was associated with improved OS, PFS, DCR, and SD, while male sex was associated with better OS and SD. Overall, regorafenib demonstrated a predictable safety profile in recurrent glioblastoma, with outcomes potentially improved in male patients with MGMT-methylated tumors.
- 1 August 2025
- Published by Springer Nature in Neuroradiology
- p. 1-12
Early venous filling following reperfusion therapy in acute ischemic stroke: a systematic review and meta-analysis
Background Early venous filling (EVF), detected by digital subtraction angiography after endovascular therapy, may indicate hyperperfusion and vascular injury. Emerging evidence suggests that EVF is associated with adverse outcomes and complications, highlighting its potential role as a prognostic imaging marker in acute ischemic stroke (AIS). Methods A systematic search was conducted in the MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies evaluating the outcomes of EVF following reperfusion therapy in cases of AIS. The outcomes included hemorrhagic transformation (HT), parenchymal hematoma (PH), hemorrhagic infarction (HI), symptomatic intracranial hemorrhage (sICH), cerebral infarction as hypodensity on imaging, malignant brain edema (MBE), and unfavorable outcome measured by modified Rankin scale (mRS ≥ 3) after 90 days. A meta-analysis using a random-effects model was conducted to pool the data. Results In the data analyses of 12 studies and 2,446 patients, the presence of EVF post-reperfusion was associated with increased risks of HT (odds ratio [OR] = 4.31; 95% confidence interval [CI] [3.00, 6.21]; p < 0.001), PH (OR = 5.73; 95% CI [2.82, 11.65]; p < 0.001), sICH (OR = 6.43; 95% CI [3.49, 8.47]; p < 0.001), cerebral infarction (OR = 15.95; 95% CI [6.37, 39.92]; p < 0.001), MBE (OR = 3.69; 95% CI [2.26, 6.04]; p < 0.001), and unfavorable functional outcomes (OR = 2.58; 95% CI [1.27, 5.23]; p = 0.009). Conclusions EVF may serve as a predictor of increased risk of hemorrhagic events, cerebral infarction on imaging, MBE, and unfavorable functional outcomes after brain reperfusion therapy. Graphical Abstract
- 1 August 2025
- Published by Springer Nature in Neuroradiology
- p. 1-12
Early venous filling following reperfusion therapy in acute ischemic stroke: a systematic review and meta-analysis
Background Early venous filling (EVF), detected by digital subtraction angiography after endovascular therapy, may indicate hyperperfusion and vascular injury. Emerging evidence suggests that EVF is associated with adverse outcomes and complications, highlighting its potential role as a prognostic imaging marker in acute ischemic stroke (AIS). Methods A systematic search was conducted in the MEDLINE, Embase, Cochrane Library, and Web of Science databases to identify studies evaluating the outcomes of EVF following reperfusion therapy in cases of AIS. The outcomes included hemorrhagic transformation (HT), parenchymal hematoma (PH), hemorrhagic infarction (HI), symptomatic intracranial hemorrhage (sICH), cerebral infarction as hypodensity on imaging, malignant brain edema (MBE), and unfavorable outcome measured by modified Rankin scale (mRS ≥ 3) after 90 days. A meta-analysis using a random-effects model was conducted to pool the data. Results In the data analyses of 12 studies and 2,446 patients, the presence of EVF post-reperfusion was associated with increased risks of HT (odds ratio [OR] = 4.31; 95% confidence interval [CI] [3.00, 6.21]; p < 0.001), PH (OR = 5.73; 95% CI [2.82, 11.65]; p < 0.001), sICH (OR = 6.43; 95% CI [3.49, 8.47]; p < 0.001), cerebral infarction (OR = 15.95; 95% CI [6.37, 39.92]; p < 0.001), MBE (OR = 3.69; 95% CI [2.26, 6.04]; p < 0.001), and unfavorable functional outcomes (OR = 2.58; 95% CI [1.27, 5.23]; p = 0.009). Conclusions EVF may serve as a predictor of increased risk of hemorrhagic events, cerebral infarction on imaging, MBE, and unfavorable functional outcomes after brain reperfusion therapy. Graphical Abstract